Feladilimab Biosimilar – Anti-ICOS mAb – Research Grade

Feladilimab Biosimilar – Anti-ICOS mAb – Research Grade Feladilimab Biosimilar – Anti-ICOS mAb – Research Grade Introduction Feladilimab Biosimilar is a monoclonal antibody (mAb) that targets the immune checkpoint protein ICOS (Inducible T-cell CO-Stimulator). It is a research grade antibody that has potential therapeutic applications in various diseases.

Structure of Feladilimab Biosimilar Feladilimab Biosimilar is a fully humanized IgG1 antibody, meaning it is derived from human cells and has a structure similar to the antibodies naturally produced by the human immune system. It consists of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa.

The variable region of Feladilimab Biosimilar is designed to specifically bind to the ICOS protein, while the constant region is responsible for the effector functions of the antibody. This structure allows Feladilimab Biosimilar to effectively target and modulate the activity of ICOS.

Mechanism of Action ICOS is a co-stimulatory molecule that is expressed on the surface of activated T-cells. It plays a crucial role in regulating the immune response by promoting T-cell activation and proliferation. However, overexpression of ICOS has been linked to the development of autoimmune diseases and cancer.

Feladilimab Biosimilar works by binding to the ICOS protein and blocking its interaction with its ligand, thereby inhibiting the downstream signaling pathways that lead to T-cell activation and proliferation. This ultimately helps to regulate the immune response and prevent the development of autoimmune diseases and cancer. Therapeutic Applications Feladilimab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including autoimmune diseases and cancer. It has the potential to be used as a monotherapy or in combination with other therapies.

In autoimmune diseases, Feladilimab Biosimilar can help to suppress the overactive immune response and reduce inflammation. This makes it a potential treatment option for diseases such as rheumatoid arthritis, multiple sclerosis, and lupus.

In cancer, Feladilimab Biosimilar can help to enhance the anti-tumor immune response by inhibiting the activity of ICOS-expressing T-cells. It has shown potential in various types of cancer, including melanoma, lung cancer, and lymphoma.

Conclusion Feladilimab Biosimilar is a research grade antibody that specifically targets the immune checkpoint protein ICOS. Its unique structure and mechanism of action make it a promising therapeutic option for various diseases, particularly autoimmune diseases and cancer. Further clinical studies are needed to fully evaluate its potential and determine its efficacy in treating these diseases.